key

pocket_crf_0.45

Spurred	VBN	VBN IN NN	O
by	IN	VBN IN NN IN	O
growth	NN	VBN IN NN IN JJ	B
in	IN	IN NN IN JJ NNS	O
world-wide	JJ	NN IN JJ NNS IN	B
sales	NNS	IN JJ NNS IN DT	I
of	IN	JJ NNS IN DT NN	O
the	DT	NNS IN DT NN POS	B
company	NN	IN DT NN POS NN	I
's	POS	DT NN POS NN NNS	B
prescription	NN	NN POS NN NNS ,	I
drugs	NNS	POS NN NNS , NNP	I
,	,	NN NNS , NNP VBD	O
Warner-Lambert	NNP	NNS , NNP VBD CD	B
said	VBD	, NNP VBD CD MD	O
1989	CD	NNP VBD CD MD VB	B
will	MD	VBD CD MD VB DT	O
be	VB	CD MD VB DT JJS	O
the	DT	MD VB DT JJS NN	B
best	JJS	VB DT JJS NN IN	I
year	NN	DT JJS NN IN PRP$	I
in	IN	JJS NN IN PRP$ NN	O
its	PRP$	NN IN PRP$ NN ,	B
history	NN	IN PRP$ NN , IN	I
,	,	PRP$ NN , IN JJ	O
with	IN	NN , IN JJ NNS	O
per-share	JJ	, IN JJ NNS VBN	B
earnings	NNS	IN JJ NNS VBN TO	I
expected	VBN	JJ NNS VBN TO VB	O
to	TO	NNS VBN TO VB JJR	O
increase	VB	VBN TO VB JJR IN	O
more	JJR	TO VB JJR IN CD	B
than	IN	VB JJR IN CD NN	I
20	CD	JJR IN CD NN TO	I
%	NN	IN CD NN TO RB	I
to	TO	CD NN TO RB $	O
about	RB	NN TO RB $ CD	B
$	$	TO RB $ CD .	I
6.10	CD	RB $ CD .	I
.	.	$ CD .	O

Sales	NNS	NNS IN DT	B
for	IN	NNS IN DT NN	O
the	DT	NNS IN DT NN VBD	B
quarter	NN	IN DT NN VBD TO	I
rose	VBD	DT NN VBD TO $	O
to	TO	NN VBD TO $ CD	O
$	$	VBD TO $ CD CD	B
1.11	CD	TO $ CD CD IN	I
billion	CD	$ CD CD IN $	I
from	IN	CD CD IN $ CD	O
$	$	CD IN $ CD CD	B
1.03	CD	IN $ CD CD .	I
billion	CD	$ CD CD .	I
.	.	CD CD .	O

Prescription-drug	NN	NN JJ NNS	B
world-wide	JJ	NN JJ NNS VBD	I
sales	NNS	NN JJ NNS VBD CD	I
rose	VBD	JJ NNS VBD CD NN	O
9	CD	NNS VBD CD NN IN	B
%	NN	VBD CD NN IN DT	I
in	IN	CD NN IN DT NN	O
the	DT	NN IN DT NN TO	B
quarter	NN	IN DT NN TO $	I
to	TO	DT NN TO $ CD	O
$	$	NN TO $ CD CD	B
340	CD	TO $ CD CD :	I
million	CD	$ CD CD : NNP	I
;	:	CD CD : NNP NNS	O
U.S.	NNP	CD : NNP NNS VBD	B
sales	NNS	: NNP NNS VBD CD	I
rose	VBD	NNP NNS VBD CD NN	O
15	CD	NNS VBD CD NN .	B
%	NN	VBD CD NN .	I
.	.	CD NN .	O

The	DT	DT NN POS	B
segment	NN	DT NN POS NN	I
's	POS	DT NN POS NN VBD	B
growth	NN	NN POS NN VBD VBN	I
was	VBD	POS NN VBD VBN IN	O
led	VBN	NN VBD VBN IN NNS	O
by	IN	VBD VBN IN NNS IN	O
sales	NNS	VBN IN NNS IN DT	B
of	IN	IN NNS IN DT JJ	O
the	DT	NNS IN DT JJ NNS	B
cardiovascular	JJ	IN DT JJ NNS NNP	I
drugs	NNS	DT JJ NNS NNP ,	I
Lopid	NNP	JJ NNS NNP , DT	B
,	,	NNS NNP , DT NN	O
a	DT	NNP , DT NN NN	B
lipid	NN	, DT NN NN ,	I
regulator	NN	DT NN NN , CC	I
,	,	NN NN , CC NNP	O
and	CC	NN , CC NNP ,	O
Dilzem	NNP	, CC NNP , DT	B
,	,	CC NNP , DT NN	O
a	DT	NNP , DT NN NN	B
calcium	NN	, DT NN NN NN	I
channel	NN	DT NN NN NN .	I
blocker	NN	NN NN NN .	I
.	.	NN NN .	O

World-wide	JJ	JJ NNS IN	B
sales	NNS	JJ NNS IN NNP	I
of	IN	JJ NNS IN NNP POS	O
Warner-Lambert	NNP	NNS IN NNP POS JJ	B
's	POS	IN NNP POS JJ NN	B
non-prescription	JJ	NNP POS JJ NN NNS	I
health-care	NN	POS JJ NN NNS ,	I
products	NNS	JJ NN NNS , JJ	I
,	,	NN NNS , JJ IN	O
such	JJ	NNS , JJ IN NNP	O
as	IN	, JJ IN NNP NN	O
Halls	NNP	JJ IN NNP NN NNS	B
cough	NN	IN NNP NN NNS ,	I
tablets	NNS	NNP NN NNS , NNP	I
,	,	NN NNS , NNP NN	O
Rolaids	NNP	NNS , NNP NN ,	B
antacid	NN	, NNP NN , CC	I
,	,	NNP NN , CC NNP	O
and	CC	NN , CC NNP NN	O
Lubriderm	NNP	, CC NNP NN NN	B
skin	NN	CC NNP NN NN ,	I
lotion	NN	NNP NN NN , VBN	I
,	,	NN NN , VBN CD	O
increased	VBN	NN , VBN CD NN	O
3	CD	, VBN CD NN TO	B
%	NN	VBN CD NN TO $	I
to	TO	CD NN TO $ CD	O
$	$	NN TO $ CD CD	B
362	CD	TO $ CD CD IN	I
million	CD	$ CD CD IN DT	I
in	IN	CD CD IN DT JJ	O
the	DT	CD IN DT JJ NN	B
third	JJ	IN DT JJ NN :	I
quarter	NN	DT JJ NN : NNP	I
;	:	JJ NN : NNP NNS	O
U.S.	NNP	NN : NNP NNS VBD	B
sales	NNS	: NNP NNS VBD NN	I
rose	VBD	NNP NNS VBD NN NN	O
5	NN	NNS VBD NN NN .	B
%	NN	VBD NN NN .	I
.	.	NN NN .	O

Confectionery	JJ	JJ NNS NNS	B
products	NNS	JJ NNS NNS RB	I
sales	NNS	JJ NNS NNS RB VBD	I
also	RB	NNS NNS RB VBD JJ	O
had	VBD	NNS RB VBD JJ NN	O
strong	JJ	RB VBD JJ NN IN	B
growth	NN	VBD JJ NN IN DT	I
in	IN	JJ NN IN DT NN	O
the	DT	NN IN DT NN .	B
quarter	NN	IN DT NN .	I
.	.	DT NN .	O

World-wide	JJ	JJ NNS IN	B
sales	NNS	JJ NNS IN NNP	I
of	IN	JJ NNS IN NNP NN	O
Trident	NNP	NNS IN NNP NN ,	B
gum	NN	IN NNP NN , NNP	I
,	,	NNP NN , NNP NN	O
Certs	NNP	NN , NNP NN NNS	B
breath	NN	, NNP NN NNS ,	I
mints	NNS	NNP NN NNS , CC	I
,	,	NN NNS , CC NNP	O
and	CC	NNS , CC NNP NN	O
Clorets	NNP	, CC NNP NN CC	B
gum	NN	CC NNP NN CC NN	I
and	CC	NNP NN CC NN NNS	I
breath	NN	NN CC NN NNS ,	I
mints	NNS	CC NN NNS , VBN	I
,	,	NN NNS , VBN CD	O
increased	VBN	NNS , VBN CD NN	O
12	CD	, VBN CD NN TO	B
%	NN	VBN CD NN TO $	I
to	TO	CD NN TO $ CD	O
$	$	NN TO $ CD CD	B
277	CD	TO $ CD CD .	I
million	CD	$ CD CD .	I
.	.	CD CD .	O

Warner-Lambert	NNP	NNP NNS VBD	B
shares	NNS	NNP NNS VBD IN	I
closed	VBD	NNP NNS VBD IN $	O
at	IN	NNS VBD IN $ CD	O
$	$	VBD IN $ CD DT	B
109.50	CD	IN $ CD DT NN	I
a	DT	$ CD DT NN ,	B
share	NN	CD DT NN , IN	I
,	,	DT NN , IN $	O
up	IN	NN , IN $ CD	O
$	$	, IN $ CD ,	B
1.50	CD	IN $ CD , IN	I
,	,	$ CD , IN NNP	O
in	IN	CD , IN NNP NNP	O
Big	NNP	, IN NNP NNP JJ	B
Board	NNP	IN NNP NNP JJ NN	I
composite	JJ	NNP NNP JJ NN NN	I
trading	NN	NNP JJ NN NN .	I
yesterday	NN	JJ NN NN .	B
.	.	NN NN .	O

Eli	NNP	NNP NNP CC	B
Lilly	NNP	NNP NNP CC NNP	I
&	CC	NNP NNP CC NNP .	I
Co	NNP	NNP CC NNP .	I
.	.	CC NNP .	I

Lilly	NNP	NNP VBD NN	B
attributed	VBD	NNP VBD NN JJ	O
record	NN	NNP VBD NN JJ CC	B
third-quarter	JJ	VBD NN JJ CC JJ	I
and	CC	NN JJ CC JJ NNS	I
nine-month	JJ	JJ CC JJ NNS TO	I
results	NNS	CC JJ NNS TO JJ	I
to	TO	JJ NNS TO JJ NNS	O
world-wide	JJ	NNS TO JJ NNS IN	B
gains	NNS	TO JJ NNS IN NNS	I
for	IN	JJ NNS IN NNS ,	O
pharmaceuticals	NNS	NNS IN NNS , JJ	B
,	,	IN NNS , JJ NNS	O
medical	JJ	NNS , JJ NNS CC	B
instruments	NNS	, JJ NNS CC NN	I
and	CC	JJ NNS CC NN NNS	O
plant-science	NN	NNS CC NN NNS IN	B
products	NNS	CC NN NNS IN JJ	I
despite	IN	NN NNS IN JJ NN	O
poor	JJ	NNS IN JJ NN NNS	B
exchange	NN	IN JJ NN NNS IN	I
rates	NNS	JJ NN NNS IN DT	I
for	IN	NN NNS IN DT NN	O
the	DT	NNS IN DT NN WDT	B
dollar	NN	IN DT NN WDT VBD	I
that	WDT	DT NN WDT VBD NNS	B
slowed	VBD	NN WDT VBD NNS RB	O
sales	NNS	WDT VBD NNS RB .	B
abroad	RB	VBD NNS RB .	O
.	.	NNS RB .	O

Earnings	NNS	NNS VBD TO	B
continued	VBD	NNS VBD TO VB	O
to	TO	NNS VBD TO VB NNS	O
pace	VB	VBD TO VB NNS IN	O
sales	NNS	TO VB NNS IN IN	B
because	IN	VB NNS IN IN DT	O
of	IN	NNS IN IN DT JJR	O
a	DT	IN IN DT JJR NN	B
lower	JJR	IN DT JJR NN NN	I
tax	NN	DT JJR NN NN ,	I
rate	NN	JJR NN NN , NN	I
,	,	NN NN , NN IN	O
profit	NN	NN , NN IN DT	B
from	IN	, NN IN DT NN	O
the	DT	NN IN DT NN IN	B
renegotiation	NN	IN DT NN IN DT	I
of	IN	DT NN IN DT NN	O
the	DT	NN IN DT NN NN	B
debt	NN	IN DT NN NN VBD	I
instrument	NN	DT NN NN VBD IN	I
received	VBD	NN NN VBD IN NNP	O
from	IN	NN VBD IN NNP NNP	O
Faberge	NNP	VBD IN NNP NNP IN	B
Inc.	NNP	IN NNP NNP IN NN	I
in	IN	NNP NNP IN NN IN	O
connection	NN	NNP IN NN IN NNP	B
with	IN	IN NN IN NNP POS	O
Lilly	NNP	NN IN NNP POS NN	B
's	POS	IN NNP POS NN IN	B
sale	NN	NNP POS NN IN NNP	I
of	IN	POS NN IN NNP NNP	O
Elizabeth	NNP	NN IN NNP NNP NNP	B
Arden	NNP	IN NNP NNP NNP IN	I
Inc.	NNP	NNP NNP NNP IN CD	I
in	IN	NNP NNP IN CD ,	O
1987	CD	NNP IN CD , CC	B
,	,	IN CD , CC JJ	O
and	CC	CD , CC JJ NNS	O
net	JJ	, CC JJ NNS IN	B
proceeds	NNS	CC JJ NNS IN DT	I
from	IN	JJ NNS IN DT NN	O
the	DT	NNS IN DT NN IN	B
settlement	NN	IN DT NN IN NN	I
of	IN	DT NN IN NN NN	O
patent	NN	NN IN NN NN IN	B
litigation	NN	IN NN NN IN NNP	I
at	IN	NN NN IN NNP POS	O
Lilly	NNP	NN IN NNP POS NNP	B
's	POS	IN NNP POS NNP NNP	B
Hybritech	NNP	NNP POS NNP NNP NN	I
Inc.	NNP	POS NNP NNP NN .	I
unit	NN	NNP NNP NN .	I
.	.	NNP NN .	O

Third-quarter	JJ	JJ NNS IN	B
sales	NNS	JJ NNS IN DT	I
of	IN	JJ NNS IN DT NNP	O
the	DT	NNS IN DT NNP ,	B
Indianapolis	NNP	IN DT NNP , NNP	I
,	,	DT NNP , NNP ,	I
Ind.	NNP	NNP , NNP , NN	I
,	,	, NNP , NN VBD	I
company	NN	NNP , NN VBD CD	I
rose	VBD	, NN VBD CD NN	O
11	CD	NN VBD CD NN TO	B
%	NN	VBD CD NN TO $	I
to	TO	CD NN TO $ CD	O
$	$	NN TO $ CD CD	B
1.045	CD	TO $ CD CD IN	I
billion	CD	$ CD CD IN $	I
from	IN	CD CD IN $ CD	O
$	$	CD IN $ CD CD	B
940.6	CD	IN $ CD CD .	I
million	CD	$ CD CD .	I
.	.	CD CD .	O

Nine-month	JJ	JJ NNS VBD	B
sales	NNS	JJ NNS VBD CD	I
grew	VBD	JJ NNS VBD CD NN	O
12	CD	NNS VBD CD NN TO	B
%	NN	VBD CD NN TO $	I
to	TO	CD NN TO $ CD	O
$	$	NN TO $ CD CD	B
3.39	CD	TO $ CD CD IN	I
billion	CD	$ CD CD IN $	I
from	IN	CD CD IN $ CD	O
$	$	CD IN $ CD CD	B
3.03	CD	IN $ CD CD DT	I
billion	CD	$ CD CD DT NN	I
a	DT	CD CD DT NN RBR	B
year	NN	CD DT NN RBR .	I
earlier	RBR	DT NN RBR .	O
.	.	NN RBR .	O

Sales	NNS	NNS IN NNP	B
of	IN	NNS IN NNP ,	O
Prozac	NNP	NNS IN NNP , DT	B
,	,	IN NNP , DT NN	O
an	DT	NNP , DT NN ,	B
anti-depressant	NN	, DT NN , VBN	I
,	,	DT NN , VBN NNS	O
led	VBN	NN , VBN NNS NNS	O
drug-sales	NNS	, VBN NNS NNS .	B
increases	NNS	VBN NNS NNS .	I
.	.	NNS NNS .	O

Higher	JJR	JJR NNS IN	B
sales	NNS	JJR NNS IN NNS	I
of	IN	JJR NNS IN NNS CC	O
pesticides	NNS	NNS IN NNS CC JJ	B
and	CC	IN NNS CC JJ NN	O
other	JJ	NNS CC JJ NN NNS	B
plant-science	NN	CC JJ NN NNS JJR	I
products	NNS	JJ NN NNS JJR IN	I
more	JJR	NN NNS JJR IN VB	O
than	IN	NNS JJR IN VB DT	O
offset	VB	JJR IN VB DT JJ	O
a	DT	IN VB DT JJ NN	B
slight	JJ	VB DT JJ NN IN	I
decline	NN	DT JJ NN IN DT	I
in	IN	JJ NN IN DT NNS	O
the	DT	NN IN DT NNS IN	B
sales	NNS	IN DT NNS IN NN	I
of	IN	DT NNS IN NN NNS	O
animal-health	NN	NNS IN NN NNS TO	B
products	NNS	IN NN NNS TO VB	I
to	TO	NN NNS TO VB DT	O
fuel	VB	NNS TO VB DT NN	O
the	DT	TO VB DT NN IN	B
increase	NN	VB DT NN IN JJ	I
in	IN	DT NN IN JJ JJ	O
world-wide	JJ	NN IN JJ JJ NN	B
agricultural	JJ	IN JJ JJ NN NNS	I
product	NN	JJ JJ NN NNS ,	I
sales	NNS	JJ NN NNS , NNP	I
,	,	NN NNS , NNP VBD	O
Lilly	NNP	NNS , NNP VBD .	B
said	VBD	, NNP VBD .	O
.	.	NNP VBD .	O

Advanced	NNP	NNP NNP NNP	B
Cardiovascular	NNP	NNP NNP NNP NNP	I
Systems	NNP	NNP NNP NNP NNP CC	I
Inc.	NNP	NNP NNP NNP CC NNP	I
and	CC	NNP NNP CC NNP NNPS	O
Cardiac	NNP	NNP CC NNP NNPS NNP	B
Pacemakers	NNPS	CC NNP NNPS NNP NNS	I
Inc.	NNP	NNP NNPS NNP NNS VBD	I
units	NNS	NNPS NNP NNS VBD NN	I
led	VBD	NNP NNS VBD NN IN	O
growth	NN	NNS VBD NN IN DT	B
in	IN	VBD NN IN DT JJ	O
the	DT	NN IN DT JJ NNS	B
medical-instrument	JJ	IN DT JJ NNS NN	I
systems	NNS	DT JJ NNS NN .	I
division	NN	JJ NNS NN .	I
.	.	NNS NN .	O

Lilly	NNP	NNP NNS VBD	B
shares	NNS	NNP NNS VBD NN	I
closed	VBD	NNP NNS VBD NN IN	O
yesterday	NN	NNS VBD NN IN JJ	B
in	IN	VBD NN IN JJ NN	O
composite	JJ	NN IN JJ NN IN	B
trading	NN	IN JJ NN IN DT	I
on	IN	JJ NN IN DT NNP	O
the	DT	NN IN DT NNP NNP	B
Big	NNP	IN DT NNP NNP IN	I
Board	NNP	DT NNP NNP IN $	I
at	IN	NNP NNP IN $ CD	O
$	$	NNP IN $ CD ,	B
62.25	CD	IN $ CD , RB	I
,	,	$ CD , RB CD	O
down	RB	CD , RB CD NNS	O
12.5	CD	, RB CD NNS .	B
cents	NNS	RB CD NNS .	I
.	.	CD NNS .	O

Reuben	NNP	NNP NNP ,	B
Mark	NNP	NNP NNP , NN	I
,	,	NNP NNP , NN IN	O
chairman	NN	NNP , NN IN NNP	B
of	IN	, NN IN NNP NNP	O
Colgate-Palmolive	NNP	NN IN NNP NNP ,	B
Co.	NNP	IN NNP NNP , VBD	I
,	,	NNP NNP , VBD PRP	O
said	VBD	NNP , VBD PRP VBZ	O
he	PRP	, VBD PRP VBZ ``	B
is	VBZ	VBD PRP VBZ `` JJ	O
``	``	PRP VBZ `` JJ ''	O
comfortable	JJ	VBZ `` JJ '' IN	O
''	''	`` JJ '' IN NNS	O
with	IN	JJ '' IN NNS POS	O
analysts	NNS	'' IN NNS POS NNS	B
'	POS	IN NNS POS NNS IN	B
estimates	NNS	NNS POS NNS IN JJ	I
that	IN	POS NNS IN JJ NNS	O
third-quarter	JJ	NNS IN JJ NNS VBD	B
earnings	NNS	IN JJ NNS VBD TO	I
rose	VBD	JJ NNS VBD TO IN	O
to	TO	NNS VBD TO IN CD	O
between	IN	VBD TO IN CD NNS	B
95	CD	TO IN CD NNS CC	I
cents	NNS	IN CD NNS CC $	I
and	CC	CD NNS CC $ CD	I
$	$	NNS CC $ CD DT	I
1.05	CD	CC $ CD DT NN	I
a	DT	$ CD DT NN .	B
share	NN	CD DT NN .	I
.	.	DT NN .	O

That	DT	DT VBZ IN	B
compares	VBZ	DT VBZ IN JJ	O
with	IN	DT VBZ IN JJ NNS	O
per-share	JJ	VBZ IN JJ NNS IN	B
earnings	NNS	IN JJ NNS IN VBG	I
from	IN	JJ NNS IN VBG NNS	O
continuing	VBG	NNS IN VBG NNS IN	B
operations	NNS	IN VBG NNS IN CD	I
of	IN	VBG NNS IN CD NNS	O
69	CD	NNS IN CD NNS DT	B
cents	NNS	IN CD NNS DT NN	I
the	DT	CD NNS DT NN RBR	B
year	NN	NNS DT NN RBR :	I
earlier	RBR	DT NN RBR : VBG	O
;	:	NN RBR : VBG VBN	O
including	VBG	RBR : VBG VBN NNS	O
discontinued	VBN	: VBG VBN NNS ,	B
operations	NNS	VBG VBN NNS , NN	I
,	,	VBN NNS , NN VBD	O
per-share	NN	NNS , NN VBD CD	B
was	VBD	, NN VBD CD NNS	O
88	CD	NN VBD CD NNS DT	B
cents	NNS	VBD CD NNS DT NN	I
a	DT	CD NNS DT NN RB	B
year	NN	NNS DT NN RB .	I
ago	RB	DT NN RB .	O
.	.	NN RB .	O

The	DT	DT JJ NNS	B
per-share	JJ	DT JJ NNS VBP	I
estimates	NNS	DT JJ NNS VBP DT	I
mean	VBP	JJ NNS VBP DT NNS	O
the	DT	NNS VBP DT NNS NN	B
consumer-products	NNS	VBP DT NNS NN POS	I
company	NN	DT NNS NN POS JJ	I
's	POS	NNS NN POS JJ NN	B
net	JJ	NN POS JJ NN ,	I
income	NN	POS JJ NN , VBN	I
,	,	JJ NN , VBN TO	O
increased	VBN	NN , VBN TO IN	O
to	TO	, VBN TO IN $	O
between	IN	VBN TO IN $ CD	B
$	$	TO IN $ CD CD	I
69.5	CD	IN $ CD CD CC	I
million	CD	$ CD CD CC $	I
and	CC	CD CD CC $ CD	I
$	$	CD CC $ CD CD	I
76	CD	CC $ CD CD ,	I
million	CD	$ CD CD , IN	I
,	,	CD CD , IN $	O
from	IN	CD , IN $ CD	O
$	$	, IN $ CD CD	B
47.1	CD	IN $ CD CD DT	I
million	CD	$ CD CD DT JJ	I
the	DT	CD CD DT JJ NN	B
year-before	JJ	CD DT JJ NN .	I
period	NN	DT JJ NN .	I
.	.	JJ NN .	O

Analysts	NNS	NNS VBP NNP	B
estimate	VBP	NNS VBP NNP POS	O
Colgate	NNP	NNS VBP NNP POS JJ	B
's	POS	VBP NNP POS JJ JJ	B
world-wide	JJ	NNP POS JJ JJ NNS	I
third-quarter	JJ	POS JJ JJ NNS VBD	I
sales	NNS	JJ JJ NNS VBD IN	I
rose	VBD	JJ NNS VBD IN CD	O
about	IN	NNS VBD IN CD NN	B
8	CD	VBD IN CD NN TO	I
%	NN	IN CD NN TO $	I
to	TO	CD NN TO $ CD	O
$	$	NN TO $ CD CD	B
1.29	CD	TO $ CD CD .	I